Skip to main content
Top

Open Access 09-05-2024 | NSCLC | Original Article

Postoperative pulmonary function of patients with lung cancer and interstitial lung abnormalities

Authors: Norifumi Tsubokawa, Takahiro Mimae, Takeshi Mimura, Atsushi Kagimoto, Atsushi Kamigaichi, Nobutaka Kawamoto, Yoshihiro Miyata, Morihito Okada

Published in: General Thoracic and Cardiovascular Surgery

Login to get access

Abstract

Objective

We investigated the impact of radiological interstitial lung abnormalities on the postoperative pulmonary functions of patients with non-small cell lung cancer.

Methods

A total of 1191 patients with clinical stage IA non-small cell lung cancer who underwent lung resections and pulmonary function tests ≥ 6 months postoperatively were retrospectively reviewed. Postoperative pulmonary function reduction rates were compared between patients with and without interstitial lung abnormalities and according to the radiological interstitial lung abnormality classifications. Surgical procedures were divided into wedge resection, 1–2 segment resection, and 3–5 segment resection groups.

Results

No significant differences in postoperative pulmonary function reduction rates 6 months after wedge resection were observed between the interstitial lung abnormality [n = 202] and non-interstitial lung abnormality groups [n = 989] [vital capacity [VC]: 6.82% vs. 5.00%; forced expiratory volume in 1 s [FEV1]: 7.05% vs. 7.14%]. After anatomical resection, these values were significantly lower in the interstitial lung abnormality group than in the non-interstitial lung abnormality group [VC: 1–2 segments, 12.50% vs. 9.93%; 3–5 segments, 17.42% vs. 14.23%; FEV1: 1–2 segments: 13.36% vs. 10.27%; 3–5 segments: 17.36% vs. 14.39%]. No significant differences in postoperative pulmonary function reduction rates according to the radiological interstitial lung abnormality classifications were observed.

Conclusions

The presence of interstitial lung abnormalities had a minimal effect on postoperative pulmonary functions after wedge resections; however, pulmonary functions significantly worsened after segmentectomy or lobectomy, regardless of the radiological interstitial lung abnormality classification in early-stage non-small cell lung cancer.
Appendix
Available only for authorised users
Literature
1.
go back to reference Washko GR, Hunninghake GM, Fernandez IE, Nishino M, Okajima Y, Yamashiro T, et al. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med. 2011;364:897–906.CrossRefPubMedPubMedCentral Washko GR, Hunninghake GM, Fernandez IE, Nishino M, Okajima Y, Yamashiro T, et al. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med. 2011;364:897–906.CrossRefPubMedPubMedCentral
2.
go back to reference Araki T, Putman RK, Hatabu H, Gao W, Dupuis J, Latourelle JC, et al. Development and progression of interstitial lung abnormalities in the framingham heart study. Am J Respir Crit Care Med. 2016;194:1514–22.CrossRefPubMedPubMedCentral Araki T, Putman RK, Hatabu H, Gao W, Dupuis J, Latourelle JC, et al. Development and progression of interstitial lung abnormalities in the framingham heart study. Am J Respir Crit Care Med. 2016;194:1514–22.CrossRefPubMedPubMedCentral
3.
go back to reference Axelsson GT, Putman RK, Araki T, Sigurdsson S, Gudmundsson EF, Eiriksdottir G, et al. Interstitial lung abnormalities and self-reported health and functional status. Thorax. 2018;73:884–6.CrossRefPubMed Axelsson GT, Putman RK, Araki T, Sigurdsson S, Gudmundsson EF, Eiriksdottir G, et al. Interstitial lung abnormalities and self-reported health and functional status. Thorax. 2018;73:884–6.CrossRefPubMed
6.
go back to reference Tomassetti S, Gurioli C, Ryu JH, Decker PA, Ravaglia C, Tantalocco P, et al. The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest. 2015;147:157–64.CrossRefPubMed Tomassetti S, Gurioli C, Ryu JH, Decker PA, Ravaglia C, Tantalocco P, et al. The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest. 2015;147:157–64.CrossRefPubMed
7.
go back to reference Sato T, Watanabe A, Kondo H, Kanzaki M, Okubo K, Yokoi K, et al. Long-term results and predictors of survival after surgical resection of patients with lung cancer and interstitial lung diseases. J Thorac Cardiovasc Surg. 2015;149(64–9):70.e1-70.e2. Sato T, Watanabe A, Kondo H, Kanzaki M, Okubo K, Yokoi K, et al. Long-term results and predictors of survival after surgical resection of patients with lung cancer and interstitial lung diseases. J Thorac Cardiovasc Surg. 2015;149(64–9):70.e1-70.e2.
8.
go back to reference Tsutani Y, Mimura T, Kai Y, Ito M, Misumi K, Miyata Y, et al. Outcomes after lobar versus sublobar resection for clinical stage I non-small cell lung cancer in patients with interstitial lung disease. J Thorac Cardiovasc Surg. 2017;154:1089-1096.e1.CrossRefPubMed Tsutani Y, Mimura T, Kai Y, Ito M, Misumi K, Miyata Y, et al. Outcomes after lobar versus sublobar resection for clinical stage I non-small cell lung cancer in patients with interstitial lung disease. J Thorac Cardiovasc Surg. 2017;154:1089-1096.e1.CrossRefPubMed
10.
go back to reference Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The iaslc lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the tnm classification for lung cancer. J Thorac Oncol. 2016;11:39–51.CrossRefPubMed Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The iaslc lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the tnm classification for lung cancer. J Thorac Oncol. 2016;11:39–51.CrossRefPubMed
11.
go back to reference Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ats/ers/jrs/alat statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.CrossRefPubMedPubMedCentral Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ats/ers/jrs/alat statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.CrossRefPubMedPubMedCentral
12.
go back to reference Mimae T, Miyata Y, Kumada T, Handa Y, Tsutani Y, Okada M. Interstitial pneumonia and advanced age negatively influence postoperative pulmonary function. Interact Cardiovasc Thorac Surg. 2022;34:753–9.CrossRefPubMedPubMedCentral Mimae T, Miyata Y, Kumada T, Handa Y, Tsutani Y, Okada M. Interstitial pneumonia and advanced age negatively influence postoperative pulmonary function. Interact Cardiovasc Thorac Surg. 2022;34:753–9.CrossRefPubMedPubMedCentral
13.
14.
go back to reference Mizobuchi T, Chen F, Yoshino I, Iwata T, Yoshida S, Bando T, et al. Radiologic evaluation for volume and weight of remnant lung in living lung donors. J Thorac Cardiovasc Surg. 2013;146:1253–8.CrossRefPubMed Mizobuchi T, Chen F, Yoshino I, Iwata T, Yoshida S, Bando T, et al. Radiologic evaluation for volume and weight of remnant lung in living lung donors. J Thorac Cardiovasc Surg. 2013;146:1253–8.CrossRefPubMed
15.
go back to reference Richeldi L, Du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071–82.CrossRefPubMed Richeldi L, Du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071–82.CrossRefPubMed
16.
go back to reference Noble PW, Albera C, Bradford WZ, Costabel U, Du Bois RM, Fagan EA, et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J. 2016;47:243–53.CrossRefPubMedPubMedCentral Noble PW, Albera C, Bradford WZ, Costabel U, Du Bois RM, Fagan EA, et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J. 2016;47:243–53.CrossRefPubMedPubMedCentral
17.
go back to reference Richeldi L, Azuma A, Cottin V, Hesslinger C, Stowasser S, Valenzuela C, et al. Trial of a preferential phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis. N Engl J Med. 2022;386:2178–87.CrossRefPubMed Richeldi L, Azuma A, Cottin V, Hesslinger C, Stowasser S, Valenzuela C, et al. Trial of a preferential phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis. N Engl J Med. 2022;386:2178–87.CrossRefPubMed
18.
go back to reference Yagihashi K, Huckleberry J, Colby TV, Tazelaar HD, Zach J, Sundaram B, et al. Radiologic-pathologic discordance in biopsy-proven usual interstitial pneumonia. Eur Respir J. 2016;47:1189–97.CrossRefPubMed Yagihashi K, Huckleberry J, Colby TV, Tazelaar HD, Zach J, Sundaram B, et al. Radiologic-pathologic discordance in biopsy-proven usual interstitial pneumonia. Eur Respir J. 2016;47:1189–97.CrossRefPubMed
19.
go back to reference De Giacomi F, White D, Cox CW, Moua T. Evolution of diagnostic UIP computed tomography patterns in idiopathic pulmonary fibrosis: disease spectrum and implications for survival. Respir Med. 2018;142:53–9.CrossRefPubMed De Giacomi F, White D, Cox CW, Moua T. Evolution of diagnostic UIP computed tomography patterns in idiopathic pulmonary fibrosis: disease spectrum and implications for survival. Respir Med. 2018;142:53–9.CrossRefPubMed
20.
go back to reference Yun JK, Lee GD, Kim HR, et al. Parsimonious risk model for predicting mortality after surgical lung biopsy for interstitial lung disease. Eur J Cardiothorac Surg. 2022;62:291.CrossRef Yun JK, Lee GD, Kim HR, et al. Parsimonious risk model for predicting mortality after surgical lung biopsy for interstitial lung disease. Eur J Cardiothorac Surg. 2022;62:291.CrossRef
21.
go back to reference Tanaka K, Tsutani Y, Wakabayashi M, Mizutani T, Aokage K, Miyata Y, et al. Sublobar resection versus lobectomy for patients with resectable stage i non-small cell lung cancer with idiopathic pulmonary fibrosis: a phase iii study evaluating survival (JCOG1708, SURPRISE). Jpn J Clin Oncol. 2020;50:1076–9.CrossRefPubMed Tanaka K, Tsutani Y, Wakabayashi M, Mizutani T, Aokage K, Miyata Y, et al. Sublobar resection versus lobectomy for patients with resectable stage i non-small cell lung cancer with idiopathic pulmonary fibrosis: a phase iii study evaluating survival (JCOG1708, SURPRISE). Jpn J Clin Oncol. 2020;50:1076–9.CrossRefPubMed
Metadata
Title
Postoperative pulmonary function of patients with lung cancer and interstitial lung abnormalities
Authors
Norifumi Tsubokawa
Takahiro Mimae
Takeshi Mimura
Atsushi Kagimoto
Atsushi Kamigaichi
Nobutaka Kawamoto
Yoshihiro Miyata
Morihito Okada
Publication date
09-05-2024
Publisher
Springer Nature Singapore
Published in
General Thoracic and Cardiovascular Surgery
Print ISSN: 1863-6705
Electronic ISSN: 1863-6713
DOI
https://doi.org/10.1007/s11748-024-02037-7
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare